Daiichi Sankyo Inc. drugs

6 results
  • enhertu - fam - trastuzumab deruxtecan - nxki injection, powder, lyophilized, for solution

    (Fam-Trastuzumab Deruxtecan-Nxki)
    Daiichi Sankyo Inc.
    ENHERTU treats HER2-positive and HER2-low/ultralow unresectable or metastatic breast cancer in adults, HER2-mutant non-small cell lung cancer, HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, and HER2-positive (IHC 3+) unresectable or metastatic solid tumors with no satisfactory alternatives.
  • savaysa - edoxaban tosylate tablet, film coated

    (Edoxaban Tosylate)
    Daiichi Sankyo Inc.
    SAVAYSA is a factor Xa inhibitor that reduces stroke and systemic embolism risk in nonvalvular atrial fibrillation, and treats deep vein thrombosis and pulmonary embolism after initial parenteral anticoagulation. Not for patients with creatinine clearance above 95 mL/min.
  • turalio - pexidartinib hydrochloride capsule

    (Pexidartinib Hydrochloride)
    Daiichi Sankyo Inc.
    Turalio treats adult patients with symptomatic tenosynovial giant cell tumor (TGCT) causing severe morbidity or functional limitations when surgery cannot improve the condition.
  • vanflyta - quizartinib tablet, film coated

    (Quizartinib)
    Daiichi Sankyo Inc.
    Vanflyta is used with chemotherapy (induction and consolidation) and as maintenance therapy to treat adults with newly diagnosed FLT3 ITD-positive acute myeloid leukemia (AML). Not indicated as maintenance after stem cell transplantation.